150 related articles for article (PubMed ID: 22407833)
1. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.
Godet Y; Fabre E; Dosset M; Lamuraglia M; Levionnois E; Ravel P; Benhamouda N; Cazes A; Le Pimpec-Barthes F; Gaugler B; Langlade-Demoyen P; Pivot X; Saas P; Maillère B; Tartour E; Borg C; Adotévi O
Clin Cancer Res; 2012 May; 18(10):2943-53. PubMed ID: 22407833
[TBL] [Abstract][Full Text] [Related]
2. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.
Alisa A; Ives A; Pathan AA; Navarrete CV; Williams R; Bertoletti A; Behboudi S
Clin Cancer Res; 2005 Sep; 11(18):6686-94. PubMed ID: 16166448
[TBL] [Abstract][Full Text] [Related]
3. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.
Dosset M; Godet Y; Vauchy C; Beziaud L; Lone YC; Sedlik C; Liard C; Levionnois E; Clerc B; Sandoval F; Daguindau E; Wain-Hobson S; Tartour E; Langlade-Demoyen P; Borg C; Adotévi O
Clin Cancer Res; 2012 Nov; 18(22):6284-95. PubMed ID: 23032748
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients.
Fonseca SG; Coutinho-Silva A; Fonseca LA; Segurado AC; Moraes SL; Rodrigues H; Hammer J; Kallás EG; Sidney J; Sette A; Kalil J; Cunha-Neto E
AIDS; 2006 Nov; 20(18):2263-73. PubMed ID: 17117012
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
6. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.
Schroers R; Huang XF; Hammer J; Zhang J; Chen SY
Cancer Res; 2002 May; 62(9):2600-5. PubMed ID: 11980655
[TBL] [Abstract][Full Text] [Related]
7. Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells.
Galaine J; Kellermann G; Guillaume Y; Boidot R; Picard E; Loyon R; Queiroz L; Boullerot L; Beziaud L; Jary M; Mansi L; André C; Lethier L; Ségal-Bendirdjian E; Borg C; Godet Y; Adotévi O
J Immunol; 2016 Sep; 197(5):1597-608. PubMed ID: 27481844
[TBL] [Abstract][Full Text] [Related]
8. Specificities and functions of CD4+ HLA class II-restricted T cell clones against a human sarcoma: evidence for several recognized antigens.
Heike M; Schlaak J; Schulze-Bergkamen H; Heyl S; Herr W; Schmitt U; Schneider PM; Meyer zum Büschenfelde KH
J Immunol; 1996 Mar; 156(6):2205-13. PubMed ID: 8690910
[TBL] [Abstract][Full Text] [Related]
9. Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients.
Godkin A; Jeanguet N; Thursz M; Openshaw P; Thomas H
Eur J Immunol; 2001 May; 31(5):1438-46. PubMed ID: 11465100
[TBL] [Abstract][Full Text] [Related]
10. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
11. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.
Warrino DE; Olson WC; Knapp WT; Scarrow MI; D'Ambrosio-Brennan LJ; Guido RS; Edwards RP; Kast WM; Storkus WJ
Clin Cancer Res; 2004 May; 10(10):3301-8. PubMed ID: 15161683
[TBL] [Abstract][Full Text] [Related]
12. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
13. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.
Klyushnenkova EN; Kouiavskaia DV; Kodak JA; Vandenbark AA; Alexander RB
Prostate; 2007 Jul; 67(10):1019-28. PubMed ID: 17455230
[TBL] [Abstract][Full Text] [Related]
14. Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen.
Klyushnenkova EN; Link J; Oberle WT; Kodak J; Rich C; Vandenbark AA; Alexander RB
Clin Cancer Res; 2005 Apr; 11(8):2853-61. PubMed ID: 15837732
[TBL] [Abstract][Full Text] [Related]
15. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
16. A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells.
Fujiki F; Oka Y; Kawakatsu M; Tsuboi A; Nakajima H; Elisseeva OA; Harada Y; Li Z; Tatsumi N; Kamino E; Shirakata T; Nishida S; Taniguchi Y; Kawase I; Oji Y; Sugiyama H
Microbiol Immunol; 2008 Dec; 52(12):591-600. PubMed ID: 19120973
[TBL] [Abstract][Full Text] [Related]
17. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ
J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154
[TBL] [Abstract][Full Text] [Related]
18. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
19. Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients.
Vetsika EK; Papadimitraki E; Aggouraki D; Konsolakis G; Mela ME; Kotsakis A; Christou S; Patramani S; Alefantinou M; Kaskara A; Christophyllakis C; Kosmatopoulos K; Georgoulias V; Mavroudis D
J Immunother; 2011; 34(9):641-50. PubMed ID: 21989412
[TBL] [Abstract][Full Text] [Related]
20. Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR.
Sun Y; Song M; Jäger E; Schwer C; Stevanovic S; Flindt S; Karbach J; Nguyen XD; Schadendorf D; Cichutek K
Clin Cancer Res; 2008 Jul; 14(13):4306-15. PubMed ID: 18594014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
